# A novel paradigm of sensitization of the tumor microenvironment with image-guided ultrasound cavitation and mechanotherapeutics for targeted HCC treatment

> **NIH NIH R01** · UNIVERSITY OF WASHINGTON · 2024 · $590,318

## Abstract

ABSTRACT
The purpose of this project is to develop a novel image-guided approach for modulating the tumor
microenvironment (TME) of HCC with combined mechanotherapeutic drugs (MechTx) and ultrasound cavitation
treatment (USCTx), and evaluate its therapeutic efficacy. We plan to implement USCTx and the targeting and
monitoring of the combined (with MechTx) treatment on a clinical scanner in order to make it widely available for
future preclinical and clinical studies. Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related
deaths worldwide with an estimated 750,000 new cases per year. Most patients with HCC who are not candidates
for surgical removal or ablation are treated with either transarterial chemoembolization or systemic
chemotherapy. Yet these treatments result in only limited improvements in patient survival at the expense of
considerable toxicities. Our main hypothesis is that the combined USCTx and MechTx will lead to tumor
pressure, stiffness and vascular changes that promote increased local tumor uptake of systemic or transarterial
chemotherapeutics, and will result in better therapy outcomes. While the discovery of new chemotherapeutic
agents and interventional procedures will continue to evolve, our approach to modulate the TME with combined
MechTx and USCTx aims to dramatically improve chemotherapy outcomes with both the existing and future
chemotherapy agents. A strong interdisciplinary team (bioengineers, scientists, clinicians) from academia and
industry will collaborate in the following aims: (Aim 1) Evaluate the ability of MechTx to modulate the tumor
microenvironment and enhance drug delivery; (Aim 2) Evaluate the ability of USCTx to modulate the tumor
microenvironment and enhance drug delivery; (Aim 3) Evaluate the ability of combined MechTx and USCTx to
modulate the tumor microenvironment and enhance drug delivery; and (Aim 4) Demonstrate the preclinical
efficacy of chemotherapeutics when combined with MechTx and USCTx in survival studies using two in vivo
models of HCC. The innovation of the project is in: (a) the use of MechTx as a novel therapeutic strategy to
modulate tumor pressure, microvascular flow, and stiffness of the TME; (b) implementing image-guided USCTx
on a clinical ultrasound scanner leading to translatable precision medicine for HCC; (c) utilizing the synergy of
MechTx and USCTx as a novel and innovative approach for modulating the TME to maximize chemotherapy
outcomes; and (d) combining super resolution and nonlinear Doppler processing to spatially and temporarily
super-resolve the vasculature of tumors undergoing treatments that target the TME. The proposed project will
take advantage of the distinct, yet synergistic mechanisms of MechTx and USCTx as a novel paradigm of
sensitization of the TME to chemotherapeutics, leading to better treatment outcomes and overall survival for
HCC patients initially and patients of other malignancies and diseases in the future.

## Key facts

- **NIH application ID:** 10853111
- **Project number:** 5R01EB032655-03
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** MICHALAKIS AVERKIOU
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $590,318
- **Award type:** 5
- **Project period:** 2022-08-15 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10853111

## Citation

> US National Institutes of Health, RePORTER application 10853111, A novel paradigm of sensitization of the tumor microenvironment with image-guided ultrasound cavitation and mechanotherapeutics for targeted HCC treatment (5R01EB032655-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10853111. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*